Subscribe to RSS
Assessment of Likelihood Ratio for Four Contact Dermatitis Symptoms of Vinca MinorFunding We received no funding for the project. The institution has no role to play in analysis of the study results and publication of the article.
06 March 2018
11 April 2018
21 May 2018 (online)
Background Contact dermatitis (CD) is a frequently occurring medical condition, for which Vinca minor (VM) is one of the recommended homeopathic medicines. However, the symptoms indicating this medicine have not yet been assessed systematically. Likelihood ratio (LR), based on Bayesian statistics, may yield better estimation of a medicine's indication than the existing method of entry of symptoms into materia medica and repertories.
Methods We investigated LRs of four CD symptoms of VM: (1) great sensitiveness of skin, with redness and soreness from slightest rubbing; (2) weeping eczema with foul, thick crusts; (3) itching amelioration in open air; and (4) CD of scalp. An observational, prospective, patient-outcome study was conducted in five different practice settings on 390 CD patients over 18 months using three outcomes—Glasgow Homeopathic Hospital Outcome Scale (GHHOS), Scoring Atopic Dermatitis (SCORAD), and Dermatology Life Quality Index (DLQI), assessed at baseline, after 3 and 6 months. The LR of each of the four symptoms was estimated as per the patient-rated outcomes on GHHOS.
Results Seventy-four VM and 316 non-VM cases were analyzed. Estimated LRs were as follows: symptom 1, 1.29 (95% confidence interval [CI]: 0.65 to 2.60); symptom 2, 1.48 (95% CI: 0.80 to 2.74); symptom 3, 1.70 (95% CI: 0.94 to 3.07); symptom 4, 1.36 (95% CI: 0.74 to 2.51). There were statistically significant reductions in SCORAD and DLQI scores over 3 and 6 months.
Conclusion There was insufficient evidence to attribute any of the four assessed symptoms clearly to VM. Though non-significant, a high LR was observed for “itching amelioration in open air” (symptom 3). Symptoms in the homeopathic materia medica for VM are perhaps over-represented. More research of this nature is warranted.
• Four symptoms of CD of VM were selected for LR estimation: (1) great sensitiveness of skin, with redness and soreness from slightest rubbing; (2) weeping eczema with foul, thick crusts; (3) itching amelioration in open air; and (4) CD of scalp.
• Though non-significant, a high LR was observed only for the symptom “Itching amelioration in open air,” and it appeared as the only probable symptom of VM as having prognostic value.
- 1 Sasseville D. Occupational contact dermatitis. Allergy Asthma Clin Immunol 2008; 4: 209-2017
- 2 Ale IS, Maibach HI. Irritant contact dermatitis. Rev Environ Health 2014; 29: 195-206
- 3 Lachapelle JM. Allergic contact dermatitis: clinical aspects. Rev Environ Health 2014; 29: 185-194
- 4 Alchorne AO, Alchorne MM, Silva MM. Occupational dermatosis. An Bras Dermatol 2010; 85: 137-145
- 5 Sarma N. Occupational allergic contact dermatitis among construction workers in India. Indian J Dermatol 2009; 54: 137-141
- 6 Anderson SE, Meade BJ. Potential health effects associated with dermal exposure to occupational chemicals. Environ Health Insights 2014; 8: 51-62
- 7 Cohen DE, Heidary N. Treatment of irritant and allergic contact dermatitis. Dermatol Ther (Heidelb) 2004; 17: 334-340
- 8 Holness DL. Occupational skin allergies: testing and treatment (the case of occupational allergic contact dermatitis). Curr Allergy Asthma Rep 2014; 14: 410
- 9 Jacobsson I, Jönsson AK, Gerdén B, Hägg S. Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden. Pharmacoepidemiol Drug Saf 2009; 18: 1039-1047
- 10 Noiesen E, Munk MD, Larsen K, Høyen M, Agner T. Use of complementary and alternative treatment for allergic contact dermatitis. Br J Dermatol 2007; 157: 301-305
- 11 Bascom A. Complementary and alternative therapies in occupational health. Part II--Specific therapies. AAOHN J 2002; 50: 468-477
- 12 Siebenwirth J, Lüdtke R, Remy W, Rakoski J, Borelli S, Ring J. Effectiveness of a classical homeopathic treatment in atopic eczema. A randomised placebo-controlled double-blind clinical trial [Article in German]. Forsch Komplement Med 2009; 16: 315-323
- 13 Keil T, Witt CM, Roll S. , et al. Homoeopathic versus conventional treatment of children with eczema: a comparative cohort study. Complement Ther Med 2008; 16: 15-21
- 14 Witt CM, Brinkhaus B, Pach D. , et al. Homoeopathic versus conventional therapy for atopic eczema in children: medical and economic results. Dermatology 2009; 219: 329-340
- 15 Witt CM, Lüdtke R, Willich SN. Homeopathic treatment of children with atopic eczema: a prospective observational study with two years follow-up. Acta Derm Venereol 2009; 89: 182-183
- 16 Itamura R, Hosoya R. Homeopathic treatment of Japanese patients with intractable atopic dermatitis. Homeopathy 2003; 92: 108-114
- 17 Rossi E, Bartoli P, Bianchi A, Da Frè M. Homeopathy in paediatric atopic diseases: long-term results in children with atopic dermatitis. Homeopathy 2012; 101: 13-20
- 18 Eizayaga JE, Eizayaga JI. Prospective observational study of 42 patients with atopic dermatitis treated with homeopathic medicines. Homeopathy 2012; 101: 21-27
- 19 Ernst E. Homeopathy for eczema: a systematic review of controlled clinical trials. Br J Dermatol 2012; 166: 1170-1172
- 20 Kent JT. Lectures on Homoeopathic Philosophy. Chapters 32, 33. New Delhi: B. Jain Publishers (P) Ltd.; 2007: 203-209
- 21 Hering C. Guiding Symptoms of Our Materia Medica. New Delhi: B. Jain Publishers (P) Ltd.; 1974
- 22 Clarke JH. A Dictionary of Practical Materia Medica. New Delhi: B. Jain Publishers (P) Ltd.; 1984
- 23 Allen TF. The Encyclopaedia of Pure Materia Medica. New Delhi: B. Jain Publishers (P) Ltd.; 2000
- 24 Boericke W. New Manual of Homeopathic Materia Medica with Repertory: 3rd Revised & Augmented Edition based on 9th edition. New Delhi: B. Jain Publishers (P) Ltd.; 2010
- 25 Choudhury NM. A Study on Materia Medica. New Delhi: B. Jain Publishers (P) Ltd.; 2009
- 26 Hempel CJ. A New and Comprehensive System of Materia Medica and Therapeutics: Arranged upon a Physiologico-pathological basis for the use of Practitioners and Students of Medicine. 3rd ed. New York: Radde; 1865
- 27 Hughes R, Dake JP. A Cyclopedia of Drug Pathogenesy. New Delhi: B. Jain Publishers; 1992
- 28 Rutten ALB, Stolper CF, Lugten RF, Barthels RW. Statistical analysis of six repertory rubrics after prospective assessment applying Bayes' theorem. Homeopathy 2009; 98: 26-34
- 29 Eizayaga JE, Pozzi MI, Canan MC, Saravia L. Prevalence and likelihood ratio of symptoms in patients with good therapeutic response to Lycopodium clavatum. A retrospective study. Homeopathy 2016; 105: 78-83
- 30 Rutten ALB, Muraleedharan KC, Shinde VH, Manchanda RK. What is a homoeopathic symptom, in daily practice and research?. Indian J Res Homoeopathy. 2017; 11: 12-20
- 31 Bayes T. An essay toward solving a problem in the doctrine of chances. Philos Trans R Soc Lond 1763; 53: 370-418
- 32 Rutten ALB, Stolper CF, Lugten RFG, Barthels RWJM. Synchronising the Repertory with Research Data. Homeopathy 2008; 97: 16-21
- 33 Rutten ALB. Prognostic factor research in homoeopathy. Indian J Res Homoeopathy. 2016; 10: 59-65
- 34 Koley M, Saha S, Das KD. , et al. Prospective evaluation of few homeopathic rubrics of Kent's repertory from Bayesian perspective. J Evid Based Complementary Altern Med 2016; 21: 277-281
- 35 Walach H, Roberti di Sarsina P, Tassinari M. Data about (complementary and alternative) medicine are irrelevant, because we are all Bayesians. Eur J Intern Med 2015; 26: e10-e11
- 36 Bikker AP, Mercer SW, Reilly D. A pilot prospective study on the consultation and relational empathy, patient enablement, and health changes over 12 months in patients going to the Glasgow Homoeopathic Hospital. J Altern Complement Med 2005; 11: 591-600
- 37 Reilly D, Mercer SW, Bikker AP, Harrison T. Outcome related to impact on daily living: preliminary validation of the ORIDL instrument. BMC Health Serv Res 2007; 7: 139
- 38 Maiti R, Sirka CS, Shaju N, Hota D. Halometasone monohydrate (0.05%) in occupational contact dermatitis. Indian J Pharmacol 2016; 48: 128-133
- 39 Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997; 195: 10-19
- 40 Charman C, Williams H. Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000; 136: 763-769
- 41 Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One 2011; 6: e17520
- 42 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216
- 43 Badia X, Mascaró JM, Lozano R. ; The Cavide Research Group. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. Br J Dermatol 1999; 141: 698-702
- 44 Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 169-180
- 45 Available at. http://sites.cardiff.ac.uk/dermatology/files/2014/04/DLQI_Bengali.pdf . Accessed March 12, 2015
- 46 Miglani A, Rutten L, Manchanda RK. Generalisability of prognostic factor research: further analysis of data from the IIPCOS2 study. Homeopathy 2017; 106: 155-159